Photopheresis Products Market Is Expected to Rise to US $371.1 Mn with a 5.9% CAGR by 2024
Photopheresis has emerged as one of the most effective treatment options for a number of autoimmune diseases, chronic graft versus host disease, solid organ transplant rejections, and advanced cutaneous T-cell lymphoma in the past few years. The therapy, which was approved by FDA in 1988, is being largely considered as the first line of treatment for a number of diseases owing to benefits such as low rate of side effects, better safety, and efficacy as compared to other drug treatments....
View full press release